BR0114407A - Mutantes de quimiocina no tratamento de esclerose múltipla - Google Patents

Mutantes de quimiocina no tratamento de esclerose múltipla

Info

Publication number
BR0114407A
BR0114407A BR0114407-3A BR0114407A BR0114407A BR 0114407 A BR0114407 A BR 0114407A BR 0114407 A BR0114407 A BR 0114407A BR 0114407 A BR0114407 A BR 0114407A
Authority
BR
Brazil
Prior art keywords
treatment
multiple sclerosis
mutants
chemokine mutants
chemokine
Prior art date
Application number
BR0114407-3A
Other languages
English (en)
Inventor
Amanda Proudfoot
Timothy N C Wells
Marie Kosco-Vilbois
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BR0114407A publication Critical patent/BR0114407A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MUTANTES DE QUIMIOCINA NO TRATAMENTO DE ESCLEROSE MúLTIPLA". Mutantes de quimiocinas CC, os quais contêm pelo menos duas mutações no local catiónico do loop 40 e os quais, com relação à molécula do tipo silvestre, têm uma atividade reduzida de ligação à GAG. Em particular, descobriu-se que tais quimiocinas que sofreram mutação são eficazes no tratamento de esclerose múltipla e/ou outras doenças de desmielinização. Um mutante triplo de RANTES é o composto que mostra melhores resultados.
BR0114407-3A 2000-10-04 2001-10-03 Mutantes de quimiocina no tratamento de esclerose múltipla BR0114407A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
BR0114407A true BR0114407A (pt) 2003-07-29

Family

ID=8170011

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114407-3A BR0114407A (pt) 2000-10-04 2001-10-03 Mutantes de quimiocina no tratamento de esclerose múltipla

Country Status (31)

Country Link
US (1) US7402303B2 (pt)
EP (1) EP1326628B1 (pt)
JP (1) JP3908165B2 (pt)
KR (1) KR100837898B1 (pt)
CN (1) CN1285381C (pt)
AR (1) AR030854A1 (pt)
AT (1) ATE265222T1 (pt)
AU (2) AU2002215919B2 (pt)
BG (1) BG66137B1 (pt)
BR (1) BR0114407A (pt)
CA (1) CA2423616C (pt)
CZ (1) CZ303409B6 (pt)
DE (1) DE60103078T2 (pt)
DK (1) DK1326628T3 (pt)
EA (1) EA006137B1 (pt)
EE (1) EE05174B1 (pt)
ES (1) ES2217199T3 (pt)
HK (1) HK1062811A1 (pt)
HR (1) HRP20030215B1 (pt)
HU (1) HUP0302194A3 (pt)
IL (2) IL155178A0 (pt)
MX (1) MXPA03003008A (pt)
NO (1) NO330278B1 (pt)
PL (1) PL204231B1 (pt)
PT (1) PT1326628E (pt)
RS (1) RS50738B (pt)
SI (1) SI1326628T1 (pt)
SK (1) SK287523B6 (pt)
UA (1) UA77950C2 (pt)
WO (1) WO2002028419A2 (pt)
ZA (1) ZA200302315B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162600A0 (en) 2001-12-17 2005-11-20 Applied Research Systems Cc-chemokine mutants as cc-chemokine antagonists
PT1494703E (pt) * 2002-04-04 2006-05-31 Applied Research Systems Quimiocinas mutantes que apresentam uma disponibilidade biologica oral melhorada
JP2006514699A (ja) * 2002-12-23 2006-05-11 アプライド リサーチ システムズ アルス ホールディング ナムローゼ フエンノートシャップ 肝疾患に対するｃｃケモカイン変異体の使用
AU2004283910A1 (en) * 2003-10-22 2005-05-06 Laboratoires Serono Sa Novel CXCL8 antagonists
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
EP1439191B1 (en) * 2004-01-19 2006-04-05 Ares Trading S.A. Process for the purification of bacterially expressed proteins
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP2218748B1 (en) * 2005-09-03 2012-10-10 Samsung SDI Co., Ltd. Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
MX2010001307A (es) 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
US9034313B2 (en) * 2010-02-08 2015-05-19 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
CA3101052A1 (en) 2018-05-28 2019-12-05 ORION Biotechnology Switzerland Sarl Methods of inhibiting cerebral inflammation
WO2022093857A1 (en) * 2020-10-26 2022-05-05 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
JP4323094B2 (ja) 1997-12-23 2009-09-02 フォンダジオーネ セントロ サン ラファエロ デル モンテ タボール Ｒａｎｔｅｓ変異体およびその治療用途
JP2002535376A (ja) 1999-01-29 2002-10-22 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Ｃｃｒ１アンタゴニストを用いた脱髄性炎症性疾患の治療方法

Also Published As

Publication number Publication date
HRP20030215A2 (en) 2005-02-28
BG66137B1 (bg) 2011-07-29
ZA200302315B (en) 2004-03-25
ES2217199T3 (es) 2004-11-01
JP2004510426A (ja) 2004-04-08
HUP0302194A3 (en) 2005-12-28
SI1326628T1 (en) 2004-10-31
DK1326628T3 (da) 2004-08-09
IL155178A (en) 2009-07-20
KR100837898B1 (ko) 2008-06-13
KR20030034238A (ko) 2003-05-01
NO20031525L (no) 2003-04-03
CA2423616C (en) 2010-03-16
EA200300439A1 (ru) 2003-08-28
PT1326628E (pt) 2004-09-30
DE60103078T2 (de) 2005-04-07
US7402303B2 (en) 2008-07-22
WO2002028419A2 (en) 2002-04-11
BG107685A (bg) 2003-11-28
NO330278B1 (no) 2011-03-21
EP1326628B1 (en) 2004-04-28
EP1326628A2 (en) 2003-07-16
EE05174B1 (et) 2009-06-15
US20040101509A1 (en) 2004-05-27
AR030854A1 (es) 2003-09-03
JP3908165B2 (ja) 2007-04-25
DE60103078D1 (de) 2004-06-03
WO2002028419A3 (en) 2002-06-13
RS50738B (sr) 2010-08-31
EA006137B1 (ru) 2005-10-27
PL204231B1 (pl) 2009-12-31
NO20031525D0 (no) 2003-04-03
YU25703A (sh) 2006-05-25
HUP0302194A2 (hu) 2003-10-28
SK4062003A3 (en) 2003-08-05
CZ303409B6 (cs) 2012-09-05
CN1285381C (zh) 2006-11-22
IL155178A0 (en) 2003-11-23
MXPA03003008A (es) 2003-07-14
ATE265222T1 (de) 2004-05-15
SK287523B6 (sk) 2011-01-04
UA77950C2 (en) 2007-02-15
CN1477969A (zh) 2004-02-25
AU1591902A (en) 2002-04-15
CA2423616A1 (en) 2002-04-11
CZ2003947A3 (cs) 2003-11-12
HK1062811A1 (en) 2004-11-26
EE200300139A (et) 2003-06-16
HRP20030215B1 (en) 2011-09-30
PL362350A1 (en) 2004-10-18
AU2002215919B2 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
BR0313059B8 (pt) composto, e, composição farmacêutica
BR0114407A (pt) Mutantes de quimiocina no tratamento de esclerose múltipla
BRPI0413051A (pt) compostos de indazol 3,5-dissubstituìdos, composições farmacêuticas e métodos para mediar ou inibir a proliferação celular
CY1114445T1 (el) Ενωσεις 2,4-πυριμιδινοδιαμινης για χρηση στη θεραπευτικη αγωγη ή προληψη αυτοανοσων ασθενειων
NO975198D0 (no) Tetralinforbindeler med MDR-aktivitet
FI935585A0 (fi) Pyrrolopyrimidiner
EA200100575A1 (ru) Соединения хинолина и хиноксалина
IT1203330B (it) Componente di catalizzatore e catalizzatore per la polimerizzazione dell'etilene o la co-polimerizzazione dell-etilene con alfa-olefine
DK1109817T3 (da) Phosphohalogenhydriner, deres fremstilling og anvendelse
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
FI920430A (fi) Benzyloxifenylderivator.
BR9814042A (pt) "compostos de tiofeno condensados e seu uso farmacêutico"
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
IL162600A0 (en) Cc-chemokine mutants as cc-chemokine antagonists
ATE49976T1 (de) Modifizierte adeninegruppe enthaltende sonde, ihre herstellung und verwendungen.
DE60239670D1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
DE69534197D1 (de) Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält
BR9709370A (pt) Gene semelhante a tolóide de mamìfero e proteìna.
BRPI0406600A (pt) Usos de citocinas isoladas, de composições farmacêuticas, composições farmacêuticas e métodos de inibição de pelo menos um dentre o recrutamento de eosinófilos ou a função de eosinófilos, o recrutamento eosinófilo pulmonar e de redução da atração quìmica eosinófilica in vivo
BR9910185A (pt) Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana
ITRM920305A0 (it) Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.
Andresen et al. A silent A to G mutation in exon 11 of the medium-chain acyl-CoA dehydrogenase (MCAD) gene
ATE247650T1 (de) Hydroxamsäure- und carbonsäurederivative
ATE397072T1 (de) Adh7-nukleotide

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SERONO S.A. (CH)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2258 DE 15/04/2014.